Table 1.

Characteristics of patients receiving renal replacement therapy by hemoglobin phenotypea

CharacteristicHbAAb (%) (n = 150)HbAS (%) (n = 28)HbAC (%) (n = 9)P
Age, years (SD)58.4 (14.8)59.8 (12.5)59.7 (16.8)0.9
Gender, n (SD)0.9
    female71 (47.3)13 (46.4)5 (55.6)
    male79 (52.7)15 (53.6)4 (44.4)
Age of ESRD onset, years (SD)54.1 (15.5)54.0 (13.8)54.5 (18.6)1.0
Dialysis vintage, median years (interquartile range)3.0 (1.2 to 5.8)5.5 (2.2 to 8.5)5.5 (1.8 to 6.5)0.05
Modality0.8
    in-center hemodialysis137 (91.3)25 (89.3)9 (100)
    peritoneal dialysis13 (8.7)3 (10.7)0
Cause of ESRDc0.1
    diabetes mellitus59 (39.3)10 (35.7)6 (66.7)
    hypertension52 (34.7)15 (53.6)1 (11.1)
    GN24 (16.0)1 (3.6)0
    cystic disease3 (2.0)00
    other12 (8.0)2 (7.1)2 (22.2)
  • aOne patient heterozygous for β-thalassemia (β-thalassemia minor, β-thalassemia trait) is not included here. This patient was a 32 year-old female on hemodialysis with hypertension as cause of ESRD and onset of ESRD at age 22.

  • bHbAA, normal adult hemoglobin phenotype.

  • cAs reported in Medicare CMS-2728 form.